Speech Topic: The Emergence of China Biotech Innovation
演讲题目：中国创新医药的崛起
Cynthia Wang, the General Manager of the I&BD Department of SERVIER (China)(施维雅中国)
Cynthia Wang Joined Servier China as Business Development Director since July 2015.
Cynthia brings with her over 19 years of Healthcare/pharmaceutical industrial experience in China. Prior to Servier China, Cynthia worked as Senior BD manager for Pfizer in Vaccine BD global M&A projects and managing full TAs of out-licensing BD activities. Before joining Pfizer, Cynthia held a series of positions in Business Development, New Product Introduction, Product launch, Strategic Alliance Management, Business planning and Operational Management at Janssen/Johnson & Johnson, Agilent Technologies and Schneider Electric. Cynthia has broad BD network in China serving as Vice Chairman of CHBD(China Healthcare BD) organization, Cynthia has proven BD track records of closing multiple BD deals.
Cynthia holds a Master of Business Administration from Peking University, a Master of Global Finance from Fordham University in NYC, a Pharmacy degree from Peking University Health Science Centre.
王昕女士于2015年7月加入施维雅中国，任职业务发展总监，专注于以中国地区的业务发展；自2020年4月起，任职法国施维雅药厂亚太生物创新中心业务拓展及许可总监，致力于通过合作和共同创造推动中国及亚太地区医疗创新。 王昕女士在中国的生命健康及制药领域工作超过19年。加入施维雅之前，王昕女士曾经任职辉瑞中国高级业务拓展经理，负责全球疫苗业务拓展和辉瑞中国对外许可项目管理。过往任职经历还包括西安杨森，安捷伦科技，施耐德电气等公司的业务发展，新产品引进及上市准备，战略联盟管理，业务规划及运营等职能。王昕女士专注于药品业务发展领域多年，拥有丰富的项目经验，同时兼任CHBD协会（中国医疗健康产业BD协会）副主席。 王昕女士的教育经历包括北京大学MBA，美国福坦姆大学国际金融硕士，北京大学医学部药学学士。
Speech Topic: New Era of Innovation and Differentiatio
演讲题目：创新与差异化的新时代
Jiaxi Xu, the Chief Analyst of Industrial Securities(兴业证券)
Dr. Xu was graduated from School of Life Sciences of Fudan University. He has rich research experience in pharma and insurance institutions. He led the team to win the No. 1 Best Analyst of New Wealth.
徐博士毕业于复旦大学生命科学学院。 在医药和保险机构有丰富的研究经验。 带领团队获得新财富最佳分析师第一名。
Speech Topic: China to Global—License out strategy
演讲题目 ：License-out: 中国企业面对MNC的谈判策略
Andy Fu, the Co-Founder & CBO of OnCusp Therapeutics(昂阔医药)
Dr. Andy Fu has over 15 years of experience in healthcare, finance, management consulting, and biotech.
Before co-founding OnCusp, Dr. Fu was Vice President of Business Development and Corporate Strategy at CStone Pharmaceuticals. As a member of the founding management team, Dr. Fu played a critical role in designing CStone’s corporate strategy and leading the business development function. He closed eight partnerships in three years, including in-licensing, out-licensing, and multi-spectrum/equity deals.
Prior to CStone, he was at Monitor Deloitte China, where he specialized in Life Sciences strategy and M&A and helped to build the Healthcare M&A practice working with some of the largest Chinese healthcare companies.
Prior to Monitor Deloitte, Dr. Fu was deputy CEO at Yanlord Financial Services based in Sydney, Australia, where he co-led multiple M&A deals. Prior to Yanlord, Dr. Fu practiced as a pharmacist at Walgreens Pharmacy.
Dr. Fu holds both a Bachelor of Pharmacy and Doctor of Pharmacy from the University of Connecticut, and an MBA from INSEAD.
富天博士在医药及金融行业、管理咨询和商务扩展方面拥有超过十五年的从业经验。在创立昂阔医药之前，他曾在基石药业担任商务拓展及企业战略副总裁。做为基石创始团队的一员，在企业战略制定和商务拓展工作方面为公司做出了极为重要的贡献。在此期间，他成功达成了授权引进、对外许可和多方股权交易在内的八项重大合作。在加入基石药业之前，富天博士曾就职德勤公司，主要负责医疗行业的战略及兼并收购业务。他参与创建的医疗行业兼并收购业务团队曾服务多家中国医疗行业的龙头企业。在加入德勤之前，曾在位于澳大利亚悉尼的仁恒金融服务公司担任副首席执行官，并共同领导完成了多项兼并收购项目。此前，他曾在美国沃尔格林连锁药房（Walgreens Pharmacy）从事药剂师工作。
富天博士拥有康涅狄格大学颁发的药剂学学士和药剂学博士学位，以及欧洲工商管理学院颁发的工商管理硕士学位。
Speech Topic: Chinese Large-cap Pharma License-in/out Strategy-Huadong Medicine Perspectives
演讲题目：中国大型药企license-in/out的交易策略 – 华东医药视角
Richard Yu, the General Manager of the I&BD Department of Huadong Medicine(华东医药)
Richard Yu joins Huadong Medicine on January 1st, 2020, as the General Manager of the Investment and BD Department of Huadong Medicine, he is mainly responsible for the license-in and investment of innovative drugs, as well as the fastening and accelerating of the transformation of Huadong Medicine through investment and product license-in.
Before joinging Huadong, he served as the BD Director of UCB and Sanofi, as well as the Director of Alliance Management of Xi’an Janssen Pharmaceutical and Deputy President of Harbour BioMed, dedicated to the Pharmaceutical investment. Richard Yu has over 20 years of experience of Pharmaceutical Investment.
余熹先生2020年1月1日加入华东医药股份有限公司，现任华东医药股份有限公司投资总经理，负责华东医药创新产品引进与投资，致力于通过投资和产品引进的方式加速和推动华东医药创新转型。
加入华东医药之前余熹先生曾任优时比制药有限公司业务发展总监，杨森制药有限公司联盟管理总监，赛诺菲BD总监以及和铂医药BD副总裁。专注药物投资和发展领域多年拥有超过20年医药投资相关经验。
Speech Topic: Status Quo and Future Development of Cell Therapy in China
演讲题目 ：细胞疗法在中国的现状与未来
Richard Wang, the Founder, Chairman and CEO of Neukio Biotherapeutics(星奕昂生物)
Dr. Richard Wang, Founder, Chairman and CEO of Neukio has extensive expertise and R&D management experience in the biopharmaceutical field in the US and China, and served as founding CEO of Fosun Kite, a joint venture between Fosun Pharma and Kite Pharma prior to establishing Neukio. He led Fosun Kite completed CMC tech transfer of Yescarta, construction of GMP production facilities, registration clinical trials and NDA filing in less than three years, and made Yescarta the first marketing approved CAR-T product in China by the NMPA.
王立群博士，星奕昂创始人，董事长兼首席执行官。王立群博士在美和中国的生物制药领域拥有丰富的专业技术和研发管理经验，曾任复星医药和美国凯特合资公司复星凯特的创始总裁。用不到三年时间完成了奕凯达的技术落地，注册临床试验，生产设施建设和上市申请，最终成为中国药监局批准上市的首个CAR-T产品。
Speech Topic: Advances in Gene Therapy and Future Prospect
演讲题目：基因治疗现状与未来展望
Alvin Luk, the CEO of NEUROPHTH THERAPEUTICS Inc.(纽福斯生物)
Dr. Alvin Luk is the Chief Executive Officer at Neurophth, bringing over 28 years of leadership experience in global drug development, strategic portfolio management and clinical development. Dr. Luk has held various management positions in clinical research and medical affairs at different companies, including Shanghai Henlius Biotech, Spark Therapeutics, Biogen-Hemophilia (acquired by Sanofi), Bayer-Schering Pharma, Avigen (acquired by Sanofi) and Tularik (acquired by Amgen) of progressive responsibilities since the late 1990s. Dr. Luk oversaw the clinical research and development, global medical affairs strategy and execution, resulting in winning the regulatory approval of 18 products in neurology, ophthalmology, hematology, gene / cell therapy and cancer therapy as of today. Spark Therapeutics’ LUXTURNA® was approved as the first gene therapy product by the FDA in 2017. Dr. Luk was the Head of Clinical Research and Operation, participated in the development of LUXTURNA®, and led the clinical development and strategy of multiple AAV gene therapy candidates. Dr. Luk also served as a member at the industrial board of the U.S. FDA Rare Diseases Clinical Design Committee, focusing on optimizing the clinical trial design to shorten drug development between 2006-2009.
Dr. Luk has published more than 85 book chapters, scientific and medical articles in highly regarded peer-reviewed journals, including New England Journal of Medicine, Nature, Cells, and Science, and is an inventor on over 10 patent applications. Dr. Luk holds an MBA from the Harvard Business School. He is ACRP-certified in clinical research and also received his Ph.D. in Neuroscience from the University of California, San Francisco.
陆英明(Alvin Luk)博士是纽福斯生物的CEO，在全球药物开发、战略、产品组合管理和临床开发方面拥有超过28年的领导经验。陆博士自90年代末便开始在不同公司担任多个行政管理职位，包括复宏汉霖、Spark Therapeutics、百健-血友病公司（被赛诺菲收购）、拜耳医药、Avigen公司（被赛诺菲收购）和Tularik公司（被安进公司收购）。陆博士负责领导临床研发、全球医疗战略和执行，先后领导或参与18种产品获得监管批准上市，产品覆盖神经科、眼科、血液科、基因/细胞治疗和癌症治疗等疾病领域。Spark Therapeutics公司的LUXTURNA®于2017年被美国FDA批准为首个基因治疗产品，陆博士届时担任临床研究和运营负责人，参与了LUXTRUNA®的开发并领导了多个AAV基因治疗临床开发和战略制定。2006至2009年期间，陆博士还担任美国食品药品监督管理局（U.S. FDA）罕见病临床设计委员会工业委员会的成员之一，专注于优化临床试验设计以缩短药物开发时间。
陆博士已在科学与医学领域前沿期刊中累计发表85多篇文章，其中包括《新英格兰医学》、《自然》、《细胞》、《科学》等杂志，并拥有10多项发明专利。陆英明博士拥有美国哈佛商学院MBA学位，并在加州大学旧金山分校获得神经科学博士学位，此外获得美国临床研究协会认证。
Speech Topic: Cross-border Licensing Annual review
演讲题目：医药跨境交易年度汇总
Sean Jiang, the CEO and Founder of YAFO Capital (雅法资本)
Mr. Jiang is a founding partner and CEO of Shanghai YAFO Capital and Co-CEO of Cukierman-YAFO Investment. He has over 15 years Wall Street experience in investment banking, M&A, and investment of in both Israeli and American technology companies. He has worked with US and China investment banks. He was the Chinese General Manager of ISI Group (NY) and Managing Director of ISI research. Before that, he was a senior research analyst at Roth Capital (LA) where he was involved in multiple cross-border transactions. When at Xiangcai Securities, a leading investment bank in Shanghai, Sean was the executive director, responsible for advising foreign institutional investors in China’s stock markets. Mr. Jiang is now a visiting professor at Concordia University (Wisconsin). He received his MBA from Pepperdine University, MA in finance from Fudan University, and BA in Economics from Central South University of China. He is a CFA Charter holder.
20+ 年华尔街及跨境投资银行、并购和投资孵化经验
雅法资本创始人，雅法专注于跨境生物医药产品引进、股权融资及并购业务，经过八年发展，成为生物医药产品跨境交易方面的领先投行
曾担任纽约著名投资机构 ISI Group (Envecore) 美国国际战略与投资集团中国部董事总经理及中国区总经理
曾任美国投资银行罗仕证券 (Roth Capital) 资深分析师
湘财证券国际业务部执行董事及国际机构客户投资部（QFII）主管
美国Pepperdine大学MBA，复旦大学金融硕士; 中南大学经济学士，美国Concordia University (Wisconsin)客座教授
CHBD（中国医疗保健业务发展协会）执行副会长， CFA Charter Holder，美国注册金融分析师协会成员
BioToChina.org 